AbbVie Signs a Worldwide License Agreement with Jacobio to Advance SHP2 Inhibitors

Shots:

• AbbVie to get an exclusive global license to develop and commercialize JAB-3068 and JAB-3312 from Jacobio
• AbbVie will provide undisclosed R&D cost to Jacobio for conducting early global CTs of JAB-3068 and JAB-3312. In addition, Jacobio has an exclusive option before registration trial initiation to develop and commercialize the SHP2 program in mainland China, Hong Kong, and Macau
• JAB-3068 and JAB-3312, are oral small molecules to inhibit SHP2 activity, a protein mediator of cellular signaling through RAS/MAP kinase pathway for the treatment of cancer

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: AbbVie